Meridian Bioscience Total Liabilities

Meridian Bioscience (VIVO) currently reports a total liabilities of $77M as of June 2025. That compares with $78M in the prior-year period — down 1.2% year over year. Use the charts on this page to explore Meridian Bioscience's total liabilities history and peer comparisons.

Meridian Bioscience's total liabilities decreased from $78M to $77M — a 1.2% year-over-year decrease (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Meridian Bioscience reported $77M in total liabilities as of June 2025. That compares with $78M in the prior-year period — down 1.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $77M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Meridian Bioscience, and consider following VIVO for alerts when major investors trade the stock.

Meridian Bioscience is classified in the Healthcare sector. On total liabilities, it currently shows $77M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VIVO with unrelated industries.